Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Emanuel BührerMichal KicinskiMario MandalaMadeline PeGeorgina V LongVictoria AtkinsonChristian U BlankAndrew HaydonStéphane DalleAdnan KhattakMatteo S CarlinoAndrey MeshcheryakovShahneen SandhuSusana PuigDirk SchadendorfRahima JamalPiotr RutkowskiAlfonsus J M van den EertweghCorneel CoensDmitri GrebennikClemens KreplerCaroline RobertAlexander M M EggermontPublished in: The Lancet. Oncology (2024)
Merck Sharp & Dohme.